Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of bevacizumab alone versus bevacizumab + capecitabine + oxaliplatin as maintenance therapy after induction CAPOX + bevacizumab in metastatic colorectal adenocarcinoma
2005-003325-67Phase 3Completed
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Nov 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of bevacizumab in colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: Tiempo hasta la progresión. Started Nov 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2005-003325-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003325-67.